Poster discussion
Bronchiectasis and NTM infections: clinical aspects and research outlook
Non CF-bronchiectasis: Aetiologic, clinical, radiological, microbiological and functional profile in a Greek population
C. Triantafyllidou(Norrköping, Sweden)
COI
1
Hacettepe University experience: Clinical evaluation of 218 primary ciliary dyskinesia patients
N. Emiralioğlu(Ankara, Turkey)
COI
2
Atorvastatin as an anti inflammatory in bronchiectasis
P. Bedi(Edinburgh (Scotland), United Kingdom)
COI
3
Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA)
R. Jimeno Galvan(Tarifa, Spain)
COI
4
Audit investigating self-management of bronchiectasis at University Hospital Llandough, Wales
S. Ali(Bristol (Avon), United Kingdom)
COI
5
A single isolation of pseudomonas aeruginosa predicts poor quality of life and increased exacerbation frequency in adult bronchiectasis
J. Hill(Dundee (Angus), United Kingdom)
COI
6
The impact of acute air pollution fluctuations on non-cystic fibrosis bronchiectasis pulmonary exacerbations: A case-crossover analysis
P. Goeminne(Bornem, Belgium)
COI
7
DLCO predicts disease severity and mortality in patients with non-cystic fibrosis bronchiectasis
M. McDonnell(Oranmore (Co Galway), Ireland)
COI
8
Increased disease severity and mortality associated with the Bronchiectasis-GORD phenotype
M. McDonnell(Oranmore (Co Galway), Ireland)
COI
9
Exacerbations and pneumonia in bronchiectasis: Clinical and microbiological characterization
V. Alcaraz-Serrano(vilafranca del penedes, Spain)
COI
10
Nontuberculous mycobacteria in the Danish population, incidence rate and clinical importance during 24 years
T. Hermansen(Rødovre, Denmark)
COI
11
Patterns of isolation and drug sensitivity in non-tuberculous mycobacteria
S. Cowman(Bath, United Kingdom)
COI
12
The value of rapid speciation of nontuberculous mycobacteria (NTM) by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF)
N. Shah(London, United Kingdom)
COI
13
Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI)
K. Olivier(Bethesda, United States)
COI
14
Feasibility study for a randomized controlled trial of pseudomonas aeruginosa eradication treatment in patients with bronchiectasis
H. Abo-Leyah(Sheffield, United Kingdom)
COI
15
Patients in randomized clinical trials of bronchiectasis are only partially representative of clinical practice: A European cohort study
J. Chalmers(Dundee (Angus), United Kingdom)
COI
16
Heterogeneity in bronchiectasis service provision in Europe: Baseline data from the European bronchiectasis registry (EMBARC)
J. Chalmers(Dundee (Angus), United Kingdom)
COI
17
. . .
